information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Sunday, 9 November 2014

ISTC (International Science&Technology Center)

 ISTC is an intergovernmental organization established in 1992 by agreement between the European Union, Japan, Russian Federation, and United States of America.
Since this time, Armenia, Belarus, Georgia, Kazakstan and the Kyrgyz Republic joined the ISTC. Norway acceded in 1997, the Republic of Korea in May 1998 and Tajikistan in March 2003.





ISTC Projects (Georgia : Eliava institute)

Click on the number for details :
 
A-2140: Phage therapy against MDR Salmonella infections, G-1021: Transmission of Water-Borne Infections, G-1028: Bacteriophages Against Intestinal Infections, G-1037: Bacteriophages for Treatment Cow Metritis and Endometritis, G-1064: Properties of Phages for Production of Preparation, G-1242: Purulent Infections of Neonates and Prevention with Bacteriophages, G-1369: Bacteriophages against Chronic Prostatitis Microflora, G-1556: Vaccine based on Phage Lysis Products, G-1666: Bacteriophage Composite against Dental Infections, G-1735: Interaction between Bacteriophages and Antibiotics, G-2055: Phage-probiotic, G-416: Anti-Anthrax Immunoglobulin, G-416.2: Anti-Anthrax Immunoglobulin, G-416.3: Anti-Anthrax Immunoglobulin, G-510: Bacteriophages Against Infectious Diseases, G-587: Genomic and Biochemical Analysis of Bacteriophage Infection, G-589: Controlled-Release Drugs with Bacteriophages, G-591: Tuberculosis Bacteriophage, G-595: Killer Proteins, G-824: Bacteriophages in Different Medicinal Forms